Embla Medical hf: Interim Report Q2 2025
Embla Medical (EMBLA) reported Q2 2025 financial results with sales of USD 232 million, showing 7% reported growth and 5% organic growth. The company's EBITDA margin reached 21% in Q2 2025, with net profit growing 5% to USD 21 million.
The Prosthetics & Neuro Orthotics segment demonstrated strong performance with 9% organic growth, while Bracing & Supports declined 2% and Patient Care remained flat. The company has narrowed its full-year organic sales growth guidance to 5-6% (from 5-8%) and maintained EBITDA margin guidance at 20-21%.
Notable developments include an agreement to acquire 51% stake in Streifeneder ortho.production, a new US reimbursement code for NEURO HiTRONIC MPKAFO, and a EUR 50 million loan from Nordic Investment Bank.
Embla Medical (EMBLA) ha comunicato i risultati finanziari del secondo trimestre 2025 con vendite pari a 232 milioni di USD, registrando una crescita segnalata del 7% e una crescita organica del 5%. Il margine EBITDA dell'azienda ha raggiunto il 21% nel Q2 2025, con un utile netto in aumento del 5% a 21 milioni di USD.
Il segmento Protesi & Neuro Ortopedia ha mostrato una solida performance con una crescita organica del 9%, mentre Bracing & Supports ha registrato un calo del 2% e Patient Care 猫 rimasto stabile. L'azienda ha ristretto la guidance sulla crescita organica delle vendite per l'intero anno al 5-6% (precedentemente 5-8%) e ha mantenuto la previsione del margine EBITDA tra il 20% e il 21%.
Tra gli sviluppi rilevanti si evidenziano un accordo per acquisire una quota del 51% in Streifeneder ortho.production, un nuovo codice di rimborso negli Stati Uniti per NEURO HiTRONIC MPKAFO e un prestito di 50 milioni di EUR dalla Nordic Investment Bank.
Embla Medical (EMBLA) report贸 los resultados financieros del segundo trimestre de 2025 con ventas de 232 millones de USD, mostrando un crecimiento reportado del 7% y un crecimiento org谩nico del 5%. El margen EBITDA de la compa帽铆a alcanz贸 el 21% en el Q2 2025, con un beneficio neto que creci贸 un 5% hasta 21 millones de USD.
El segmento de Pr贸tesis y Neuro Ortopedia mostr贸 un desempe帽o s贸lido con un crecimiento org谩nico del 9%, mientras que Bracing & Supports disminuy贸 un 2% y Patient Care se mantuvo estable. La empresa ha ajustado su previsi贸n de crecimiento org谩nico de ventas para todo el a帽o a un rango de 5-6% (desde 5-8%) y mantuvo la gu铆a del margen EBITDA en 20-21%.
Entre los desarrollos destacados se incluyen un acuerdo para adquirir una participaci贸n del 51% en Streifeneder ortho.production, un nuevo c贸digo de reembolso en EE.UU. para NEURO HiTRONIC MPKAFO y un pr茅stamo de 50 millones de EUR del Nordic Investment Bank.
Embla Medical (EMBLA)鞚� 2025雲� 2攵勱赴 鞛 鞁れ爜鞚� 氚滍憸頃橂┌ 毵れ稖鞎� 2鞏� 3,200毵� 雼煬毳� 旮半, 氤搓碃 旮办 靹膘灔毳� 7%鞕� 鞙犼赴鞝� 靹膘灔毳� 5%毳� 氤挫榾鞀惦媹雼�. 須岇偓鞚� EBITDA 毵堨鞚� 2025雲� 2攵勱赴鞐� 21%鞐� 霃勲嫭頄堨溂氅�, 靾滌澊鞚奠潃 5% 歃濌皜頃� 2,100毵� 雼煬毳� 旮半頄堨姷雼堧嫟.
氤挫矤 氚� 鞁犼步 鞝曧槙鞕戈臣 攵�氍胳潃 9%鞚� 鞙犼赴鞝� 靹膘灔鞚� 氤挫澊氅� 臧曧暅 鞁れ爜鞚� 雮橅儉雮� 氚橂┐, 氤挫“旮� 氚� 歆�歆�雽� 攵�氍胳潃 2% 臧愳唽頄堦碃 頇橃瀽 甏�毽� 攵�氍胳潃 氤�霃欖澊 鞐嗢棃鞀惦媹雼�. 須岇偓電� 鞐瓣皠 鞙犼赴鞝� 毵れ稖 靹膘灔 鞝勲鞚� 5-6%搿� 膦來様鞙茧┌(旮办〈 5-8%), EBITDA 毵堨 鞝勲鞚� 20-21%搿� 鞙犾頄堨姷雼堧嫟.
欤检殧 氚滌爠 靷暛鞙茧電� Streifeneder ortho.production鞚� 51% 歆�攵� 鞚胳垬 瓿勳暯, NEURO HiTRONIC MPKAFO鞐� 雽�頃� 氙戈淡 雮� 靸堧鞖� 靸來櫂 旖旊摐, 攴鸽Μ瓿� 雲鸽ゴ霐� 韴瀽鞚�頄夓溂搿滊秬韯办潣 5,000毵� 鞙犽 雽�於�鞚� 韽暔霅╇媹雼�.
Embla Medical (EMBLA) a publi茅 ses r茅sultats financiers du deuxi猫me trimestre 2025 avec un chiffre d'affaires de 232 millions de dollars, affichant une croissance rapport茅e de 7 % et une croissance organique de 5 %. La marge EBITDA de la soci茅t茅 a atteint 21 % au T2 2025, avec un b茅n茅fice net en hausse de 5 % 脿 21 millions de dollars.
Le segment Proth猫ses & Neuro-Orthop茅die a d茅montr茅 une solide performance avec une croissance organique de 9 %, tandis que Bracing & Supports a diminu茅 de 2 % et Patient Care est rest茅 stable. L'entreprise a resserr茅 ses pr茅visions de croissance organique des ventes annuelles 脿 5-6 % (au lieu de 5-8 %) et a maintenu ses pr茅visions de marge EBITDA entre 20 et 21 %.
Parmi les d茅veloppements notables figurent un accord pour acqu茅rir une participation de 51 % dans Streifeneder ortho.production, un nouveau code de remboursement am茅ricain pour le NEURO HiTRONIC MPKAFO, ainsi qu'un pr锚t de 50 millions d'euros accord茅 par la Nordic Investment Bank.
Embla Medical (EMBLA) meldete die Finanzergebnisse f眉r das zweite Quartal 2025 mit einem Umsatz von 232 Millionen USD, was einem berichteten Wachstum von 7 % und einem organischen Wachstum von 5 % entspricht. Die EBITDA-Marge des Unternehmens erreichte im Q2 2025 21%, w盲hrend der Nettogewinn um 5 % auf 21 Millionen USD stieg.
Der Bereich Prothetik & Neuro-Orthop盲die zeigte eine starke Leistung mit einem organischen Wachstum von 9%, w盲hrend Bracing & Supports um 2 % zur眉ckging und Patient Care stabil blieb. Das Unternehmen hat seine Prognose f眉r das organische Umsatzwachstum im Gesamtjahr auf 5-6% (vorher 5-8%) eingegrenzt und die EBITDA-Margen-Prognose bei 20-21 % belassen.
Zu den bemerkenswerten Entwicklungen z盲hlen eine Vereinbarung zum Erwerb eines 51% Anteils an Streifeneder ortho.production, ein neuer US-Erstattungscode f眉r NEURO HiTRONIC MPKAFO sowie ein 50 Millionen EUR Darlehen von der Nordic Investment Bank.
- EBITDA margin improved to 21% in Q2 2025 from 19% in H1 2024
- Strong 9% organic growth in Prosthetics & Neuro Orthotics segment
- Net profit grew 17% in H1 2025
- Strategic acquisition of 51% stake in Streifeneder ortho.production
- New US reimbursement code obtained for NEURO HiTRONIC MPKAFO
- EUR 50 million loan secured from Nordic Investment Bank
- Organic growth slowed to 5% compared to 6% in Q2 2024
- Bracing & Supports segment declined by 2% organic growth
- Patient Care segment showed flat growth vs 9% in Q2 2024
- Gross profit margin decreased to 62% from 64% in Q2 2024
- Free cash flow reduced to 5% of sales from 8% in Q2 2024
- Full-year organic growth guidance narrowed downward to 5-6% from 5-8%
Insights
Embla Medical delivers solid Q2 with 5% organic growth, EBITDA margin improvement to 21%, and a strategic acquisition announcement.
Embla Medical's Q2 2025 results demonstrate solid performance despite mixed segment results. The company reported
Profitability metrics were strong with an EBITDA margin of
Net profit grew
The company's strategic developments include a pending majority stake (51%) acquisition in Streifeneder ortho.production, a company with
Management has narrowed guidance for 2025 organic sales growth to
Announcement no. 33/2025
Interim report Q2 2025
22 July 2025
Sveinn S枚lvason, President and CEO, comments:
"Sales in Q2 2025 amounted to
The EBITDA听margin听was听strong at
In line with our performance in the first half of the year and expectations for stronger growth in the second half, we are narrowing our full-year guidance for organic sales growth to 5
Highlights Q2 2025
- Sales amounted to
USD 232 million and organic growth was5% , compared to6% in Q2 2024. - Prosthetics & Neuro Orthotics sales grew by
9% organic, Bracing & Supports (B&S) sales declined by2% organic and Patient Care sales were flat, compared to6% ,2% and9% respectively in Q2 2024. - Gross profit margin was
62% , compared to64% in Q2 2024. For 1H 2025 the gross profit margin increased to63% compared to62% in the same period 2024. The gross profit margin in the quarter was positively impacted from strong performance in Prosthetics & Neuro Orthotics, in addition to efficiency in manufacturing, but the margin was adversely impacted by soft sales in B&S and Patient Care due to lower scale on fixed manufacturing cost, in addition to some impact from US tariffs. - EBITDA was
USD 49 million , and EBITDA margin was21% of sales, compared to22% in Q2 2024. EBITDA margin in the 1H 2025 was20% compared to19% before special items in 1H 2024. The EBITDA margin in the quarter was positively impacted by solid cost discipline in SG&A but negatively impacted by a softer gross profit margin than in the comparable period. - Net profit grew by
5% and wasUSD 21 million , and the net profit margin was9% of sales, the same as in Q2 2024. Net profit growth was17% in 1H 2025. Net profit in Q2 and 1H was negatively impacted by net exchange differences. - Free cash flow amounted to
USD 12 million or5% of sales, compared to8% of sales in Q2 2024. Free cash flow benefitted from strong operating results but was partly offset by temporary working capital investments and elevated CAPEX in the quarter. - NIBD/EBITDA before special items was 2.6x at the end of Q2 2025. The leverage ratio is within the target range of 2.0-3.0x and the share buyback program is ongoing. Embla Medical bought back 627,624 shares for approximately
USD 3 million in the quarter.
Other highlights
- Agreement signed on 17 July 2025 to invest in a majority share (
51% of the shares) in privately owned Streifeneder ortho.production GmbH, an international developer and supplier of orthopaedic mobility solutions, employing around 100 people, with sales ofEUR 25 million in 2024 (USD 29 million). Closing of the transaction is subject to regulatory approval.听 - Fior & Gentz (Neuro Orthotics) has been awarded a new reimbursement code in
the United States (L-2006 code) for the 'NEURO HiTRONIC MPKAFO' (bionic knee joint), which is the smallest and lightest microhydraulic knee joint on the market, a significant milestone in the introduction of Neuro Orthotics products inthe United States . EUR 50 million loan signed with Nordic Investment Bank (NIB).- Halfway through unifying our Patient Care facilities under the ForMotion brand. Patient care facilities in
Iceland ,Sweden , andFinland were rebranded to ForMotion in Q2 2025.
2025 Outlook
- Organic sales growth guidance narrowed to 5
-6% (previously 5-8% ) - EBITDA margin before special items guidance is unchanged at 20
-21%
*听Potential impact from US trade tariffs continues to be an uncertain element to quantify given the frequent changes in the global tariff environment. Consequently, we deem it too speculative to quantify and guide an exact impact from potential tariffs on Embla Medical's financial results, but some absorption of tariffs is assumed in the guidance.
Conference call details
Embla Medical will host a conference call on July 22, 2025, at 9:00 CET / 7:00 GMT / 3:00 ET.
To actively participate in the telephone conference, please use the dial-in details provided below:
DK: +45 78 76 84 90
SE: +46 31-311 50 03
US: +1 646 787 0157
Participant access code: 274982
The webcast will be available through following link:
Latest Investor Road Show presentation can be found on our IR web:
Further information
Klaus Sindahl, Head of Investor Relations, [email protected], +45 5363 0134
Embla Medical press releases by e-mail
If you wish to receive Embla Medical press releases by e-mail, please register at
About Embla Medical
Embla Medical (Nasdaq Copenhagen: EMBLA) was founded in
Embla Medical was formerly listed as 脰ssur (OSSR) on Nasdaq Copenhagen until 8 April 2024.
This information was brought to you by Cision .
https://news.cision.com/embla-medical-hf-/r/embla-medical-hf--interim-report-q2-2025,c4209713
The following files are available for download:
| Company Announcement Q2 2025 incl. Financial Statement FINAL |
听
View original content:
SOURCE Embla Medical hf.
FAQ
What were Embla Medical's (EMBLA) key financial results for Q2 2025?
How did Embla Medical's different segments perform in Q2 2025?
What is Embla Medical's updated guidance for 2025?
What major strategic developments did Embla Medical announce in Q2 2025?
How did Embla Medical's gross profit margin change in Q2 2025?
What is Embla Medical's current debt position?
